Literature DB >> 9369928

Regressive effects of various chemopreventive agents on azoxymethane-induced aberrant crypt foci in the rat colon.

Y Morishita1, N Yoshimi, K Kawabata, K Matsunaga, S Sugie, T Tanaka, H Mori.   

Abstract

Regressive effects of four chemopreventive agents [5-hydroxy-4-(2-phenyl-(E)-ethenyl)-2(5H)-furanone (KYN-54), S-methyl methanethiosulfonate (MMTS), chlorogenic acid (CA), and piroxicam] on azoxymethane (AOM)-induced aberrant crypt foci (ACF) in the colon of male F344 rats were examined by dietary exposure. At six weeks of age, 60 rats of groups 1 through 5 received subcutaneous injections of AOM (15 mg/kg body weight) once a weeks. Twelve weeks after the first carcinogen injection, when the occurrence of ACF was maximal, the rats in groups 2 through 5 were started on diet containing the test chemicals as follows: group 2, KYN-54 (0.02%); group 3, MMTS (0.01%); group 4, CA (0.025%); and group 5, piroxicam (0.0125%). Group 1 (20 rats) was kept on the basal diet alone, and group 6 (12 rats) served as an untreated control. Rats in each group were killed at 6, 12, 18, or 24 weeks after the start of the experiment, and the yield of ACF in the colon of each group at 18 or 24 weeks was compared with that at 12 weeks. The number of ACF per rat colon of each group at 18 or 24 weeks was smaller than that at 12 weeks. The reduction rates at 18 weeks were 7% in group 1 (AOM alone), 11% in group 2 (AOM + KYN-54), 10% in group 3 (AOM + MMTS), 51% in group 4 (AOM + CA) (P < 0.01), and 33% in group 5 (AOM + piroxicam) (P < 0.02), while at 24 weeks they were 12%, 26%, 51% (P < 0.002), 43% (P < 0.05), and 70% (P < 0.001), respectively. These results indicate that chemopreventive agents for large bowel carcinogenesis, i.e., KYN-54, MMTS, CA, and piroxicam, are not only able to prevent the development of ACF, but also can regress ACF, which are regarded as precursor lesions of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369928      PMCID: PMC5921511          DOI: 10.1111/j.1349-7006.1997.tb00456.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  22 in total

1.  Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion.

Authors:  H S Samaha; G J Kelloff; V Steele; C V Rao; B S Reddy
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

Review 2.  Role of aberrant crypt foci in understanding the pathogenesis of colon cancer.

Authors:  R P Bird
Journal:  Cancer Lett       Date:  1995-06-29       Impact factor: 8.679

3.  Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents.

Authors:  M A Pereira; L H Barnes; V L Rassman; G V Kelloff; V E Steele
Journal:  Carcinogenesis       Date:  1994-05       Impact factor: 4.944

4.  Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development.

Authors:  B S Reddy; H Maruyama; G Kelloff
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

5.  Inhibitory effect of chlorogenic acid on methylazoxymethanol acetate-induced carcinogenesis in large intestine and liver of hamsters.

Authors:  H Mori; T Tanaka; H Shima; T Kuniyasu; M Takahashi
Journal:  Cancer Lett       Date:  1986-01       Impact factor: 8.679

6.  Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate.

Authors:  T P Pretlow; M A O'Riordan; G A Somich; S B Amini; T G Pretlow
Journal:  Carcinogenesis       Date:  1992-09       Impact factor: 4.944

7.  Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis.

Authors:  S J Shiff; M I Koutsos; L Qiao; B Rigas
Journal:  Exp Cell Res       Date:  1996-01-10       Impact factor: 3.905

8.  Chemoprevention of azoxymethane-induced intestinal carcinogenesis by a novel synthesized retinoidal butenolide, 5-hydroxy-4-(2-phenyl-(E)-ethenyl)-2(5H)-furanone, in rats.

Authors:  T Kawamori; T Tanaka; M Suzui; K Okamoto; Y Tamai; M Torihara; J Yamahara; H Mori
Journal:  Carcinogenesis       Date:  1995-04       Impact factor: 4.944

9.  Modifying effects of naturally occurring products on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats.

Authors:  T Kawamori; T Tanaka; A Hara; J Yamahara; H Mori
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

10.  Aberrant crypts: putative preneoplastic foci in human colonic mucosa.

Authors:  T P Pretlow; B J Barrow; W S Ashton; M A O'Riordan; T G Pretlow; J A Jurcisek; T A Stellato
Journal:  Cancer Res       Date:  1991-03-01       Impact factor: 12.701

View more
  4 in total

Review 1.  Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency.

Authors:  Denis E Corpet; Sylviane Taché
Journal:  Nutr Cancer       Date:  2002       Impact factor: 2.900

Review 2.  The potential effects of chlorogenic acid, the main phenolic components in coffee, on health: a comprehensive review of the literature.

Authors:  Narges Tajik; Mahboubeh Tajik; Isabelle Mack; Paul Enck
Journal:  Eur J Nutr       Date:  2017-04-08       Impact factor: 5.614

3.  Caffeine and Chlorogenic Acid Combination Attenuate Early-Stage Chemically Induced Colon Carcinogenesis in Mice: Involvement of oncomiR miR-21a-5p.

Authors:  Ariane Rocha Bartolomeu; Guilherme Ribeiro Romualdo; Carmen Griñán Lisón; Zein Mersini Besharat; Juan Antonio Marchal Corrales; Maria Ángel García Chaves; Luís Fernando Barbisan
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

4.  Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats.

Authors:  H Kohno; S Yoshitani ; S Takashima; A Okumura; M Hosokawa; N Yamaguchi; T Tanaka
Journal:  Jpn J Cancer Res       Date:  2001-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.